ABPI response to guidance on the value of new antibiotics

The Association of the British Pharmaceutical Industry has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics.

It is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients. Richard Torbett

Commenting on the announcement of the new draft guidance, Richard Torbett, Chief Executive of the ABPI said:

“This is an important milestone in the UK’s global leadership on AMR.

"Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. 

"To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

"We acknowledge the difficulties of generating evidence on the broader public health benefits that antibiotics bring to patients, but it is essential these are fully captured in evaluation frameworks. 

"Rapid progress is needed to establish a permanent evaluation and reimbursement approach and deliver the incentives needed to develop these important medicines.

"Only then will patients across the whole UK be confident that they can access effective antibiotics now and into the future.”

TAGS
  • AMR

The public health benefits described above relate to the following attributes known as STEDI.  It is vital that evaluation captures the full value of antibiotics by ensuring all elements are included in the criteria.

STEDI

1.    Spectrum: Benefits of being able to treat with a narrow-spectrum agent in some settings

2.    Transmission: Benefits from avoiding the spread of infection

3.    Enablement: Benefits from making it safe to receive medical care

4.    Diversity: Using varied antibiotics reduces resistance pressure

5.    Insurance: Value of having an antibiotic to hand in case of sudden need

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.